Apollo Neuroscience is a technology company.
Apollo Neuroscience has raised $6.0M across 1 funding round.
Apollo Neuroscience has raised $6.0M in total across 1 funding round.
Apollo Neuroscience has raised $6.0M in total across 1 funding round.
Apollo Neuroscience's investors include ACME Capital, AIX Ventures, Khosla Ventures, Polychain Capital, Primer Sazze Partners, SeaX Ventures, Shervin Pishevar.
Apollo Neuroscience is a consumer wellness technology company that develops wearable devices to manage stress, improve sleep, focus, and recovery through non-invasive touch therapy.[1][2][3] Its flagship product, the Apollo wearable, is a vibrating wristband that delivers soothing, low-frequency vibrations—called Apollo Vibes™—to activate the vagus nerve and rebalance the autonomic nervous system, mimicking the effects of meditation without drugs or screens.[2][3][4] Targeting high-achievers like athletes and executives as well as general users seeking better well-being, it addresses chronic stress and poor sleep by promoting parasympathetic activation for relaxation and sympathetic engagement for focus.[1][5][7] With over 150,000 users, 17 completed clinical studies, and integrations like Apple Health and Oura Ring, Apollo shows strong growth momentum, including a 2023 launch of AI-driven SmartVibes for personalized sleep support adding up to 60 minutes of deeper sleep nightly.[3][4][5]
Apollo Neuroscience spun out of neuroscience research at the University of Pittsburgh in 2017, founded by psychiatrist and neuroscientist Dr. David Rabin MD, PhD, who explored how soothing vibrations could leverage the body's natural touch response to restore nervous system balance.[2][5] Dr. Rabin's work built on decades of studies into vibration frequencies' impact on the body, addressing modern stressors that keep the sympathetic "fight-or-flight" system overactive, leading to poor sleep and focus.[5][7] The idea emerged from lab experiments confirming vibrations could measurably improve heart rate variability (HRV)—a key marker of stress resilience—prompting the 2020 market launch of the Apollo wearable.[2][5] Early traction came from peer-reviewed validation as the first health tech wearable beyond mere tracking, attracting over 100,000 users by 2023 and expanding to AI enhancements.[2][3]
Apollo stands out in the crowded wearables market by actively intervening in physiology rather than just monitoring it. Key advantages include:
| Feature | Apollo (Soothing) | Typical Tracking Wearables |
|---|---|---|
| Core Function | Active vagus nerve stimulation via vibrations | Passive biometric monitoring |
| HRV Impact | Improves via intervention | Tracks only |
| Usage | Passive, app-optional | App-dependent |
| Sleep Gains | +30-60 min deep/REM | Reports scores |
| Invasiveness | Non-invasive, no chemicals | None, but no therapy |
Apollo rides the exploding wellness tech wave, fueled by post-pandemic demand for mental health tools amid rising chronic stress, with the sleep tech market segmenting into wearables for OSA, insomnia, and more across North America and beyond.[1][2] Its timing aligns perfectly with AI integration in health (e.g., SmartVibes) and a shift from passive trackers to active neuromodulation devices, positioning it against competitors like ReliefBand while pioneering vagus nerve stimulation for everyday use.[1][3][7] Market forces like FDA clearances for sleep devices and consumer preference for non-drug solutions favor Apollo, influencing the ecosystem by validating university-spun neurotech and inspiring "soothing wearables" that enhance performance without screens.[2][5] As HRV optimization gains traction in executive and athletic circles, Apollo accelerates the trend toward resilient, biohacked nervous systems.
Apollo Neuroscience is poised to dominate active wellness wearables, expanding SmartVibes AI for deeper personalization and potential B2B plays in corporate wellness or sports performance.[3][5] Trends like AI-driven health interventions, rising vagus nerve research, and integration with ecosystems (e.g., more wearables) will propel growth, especially as clinical data accumulates beyond its 17 studies. Its influence may evolve from consumer disruptor to category leader, retraining nervous systems at scale for a less-stressed world—turning the Pittsburgh lab breakthrough into everyday resilience.[2][5] This positions Apollo as a smart bet in the multibillion-dollar sleep-stress tech surge, delivering tangible calm where trackers fall short.
Apollo Neuroscience has raised $6.0M across 1 funding round. Most recently, it raised $6.0M Series A in May 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2021 | $6.0M Series A | ACME Capital, AIX Ventures, Khosla Ventures, Polychain Capital, Primer Sazze Partners, SeaX Ventures, Shervin Pishevar |